Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review
作者： Giuseppe Floresta , Venerando Pistarà , Emanuele Amata , Maria Dichiara , Agostino Marrazzo
DOI: 10.1016/J.EJMECH.2017.07.022
关键词:
摘要: Small molecule inhibitors of adipocyte fatty acid binding protein 4 (FABP4) have attracted interest following the recent publications beneficial pharmacological effects these compounds. FABP4 is predominantly expressed in macrophages and adipose tissue where it regulates acids (FAs) storage lipolysis an important mediator inflammation. In past years, hundreds been synthesized for effective atherosclerosis diabetes treatments, including derivatives niacin, quinoxaline, aryl-quinoline, bicyclic pyridine, urea, aromatic compounds other novel heterocyclic This review provides overview discovered molecules as (FABP4is) since synthesis putative FABP4i, BMS309403, highlighting interactions different classes with targets.
elsevier.com
sci-hub.se 参考文章(74)
R.S. Sha, C.D. Kane, Z. Xu, L.J. Banaszak, D.A. Bernlohr, Modulation of ligand binding affinity of the adipocyte lipid-binding protein by selective mutation. Analysis in vitro and in situ. Journal of Biological Chemistry. ,vol. 268, pp. 7885- 7892 ,(1993) , 10.1016/S0021-9258(18)53040-4
Guenther Boden, Free fatty acids FFA a link between obesity and insulin resistance Frontiers in Bioscience. ,vol. 3, pp. d169- 175 ,(1998) , 10.2741/A272
R. A. Defronzo, Dysfunctional fat cells, lipotoxicity and type 2 diabetes International journal of clinical practice. Supplement. ,vol. 58, pp. 9- 21 ,(2004) , 10.1111/J.1368-504X.2004.00389.X
Mary YK Lee, Huiying Li, Yang Xiao, Zhiguang Zhou, Aimin Xu, Paul M Vanhoutte, Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells British Journal of Pharmacology. ,vol. 162, pp. 1564- 1576 ,(2011) , 10.1111/J.1476-5381.2010.01158.X
Tiziana Beringhelli, Elisabetta Gianazza, Daniela Maggioni, Sandra Scanu, Chiara Parravicini, Cristina Sensi, Hugo L. Monaco, Ivano Eberini, All-Purpose Containers? Lipid-Binding Protein – Drug Interactions PLOS ONE. ,vol. 10, pp. 1- 22 ,(2015) , 10.1371/JOURNAL.PONE.0132096
Kenjiro TADERA, Yuji MINAMI, Kouta TAKAMATSU, Tomoko MATSUOKA, Inhibition of α-Glucosidase and α-Amylase by Flavonoids Journal of Nutritional Science and Vitaminology. ,vol. 52, pp. 149- 153 ,(2006) , 10.3177/JNSV.52.149
Hisanori Uehara, Tetsuyuki Takahashi, Mina Oha, Hirohisa Ogawa, Keisuke Izumi, Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. International Journal of Cancer. ,vol. 135, pp. 2558- 2568 ,(2014) , 10.1002/IJC.28903
Gökhan S. Hotamisligil, David A. Bernlohr, Metabolic functions of FABPs—mechanisms and therapeutic implications Nature Reviews Endocrinology. ,vol. 11, pp. 592- 605 ,(2015) , 10.1038/NRENDO.2015.122
Soha Abdelkawi Abdelwahab, Yuji Owada, Noriko Kitanaka, Anne Adida, Hiroyuki Sakagami, Masao Ono, Makoto Watanabe, Friedrich Spener, Hisatake Kondo, Enhanced expression of adipocyte-type fatty acid binding protein in murine lymphocytes in response to dexamethasone treatment. Molecular and Cellular Biochemistry. ,vol. 299, pp. 99- 107 ,(2007) , 10.1007/S11010-005-9050-1
DOKSA LEE, KOICHIRO WADA, YOSHITAKA TANIGUCHI, HANI AL-SHAREEF, TOMOTAKE MASUDA, YU USAMI, TOMONAO AIKAWA, MASAYA OKURA, YOSHINORI KAMISAKI, MIKIHIKO KOGO, Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma Oncology Reports. ,vol. 31, pp. 1116- 1120 ,(2014) , 10.3892/OR.2014.2975